InflaRx概述了Vilobelimab治疗坏疽性脓皮病的3期研究的多个数据分析，该研究于2025年初终止，此前独立数据监测委员会因无效而建议提前停止试验

2025-12-30 20:32

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect
InflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in collaboration with a partner